Reich K, Sullivan J, Arenberger P, et al. - In this 32-week results from the randomized placebo-controlled TRANSFIGURE trial, researchers analyzed the superiority of secukinumab over placebo in clearing nail psoriasis as evaluated by the Nail Psoriasis Severity Index (NAPSI) at week 16 and overtime up to week 132. Nail Assessment in Psoriasis and Psoriatic Arthritis patient questionnaires evaluated the impact on the quality of life. The primary objective of this investigation was met: at week 16, both doses of secukinumab were higher than placebo (NAPSI improvements of −45·3%, −37·9% and −10·8% for secukinumab 300 mg and 150 mg and placebo, respectively). For patients with nail psoriasis up to week 32, secukinumab showed significant and clinically meaningful effectiveness and quality-of-life improvements. Nasopharyngitis, headache and upper respiratory tract infections were the most common adverse events.